FDA drug chief Dr. George Tidmarsh resigned amid an internal review into alleged misconduct, following a lawsuit from Aurinia Pharmaceuticals accusing him of defamation. Aurinia’s stock plunged 20% after Tidmarsh criticized its kidney drug on LinkedIn. His exit adds to turmoil at an FDA division already facing heavy staff losses.